Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Stocks Pressured by Rising Oil Prices and Bond Yields

View original at nasdaq.com
Stocks Pressured by Rising Oil Prices and Bond Yields The S&P 500 Index ($SPX) (SPY) today is down -0.26%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.80%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.16%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Inflation is a bigger concern than economic growth as ECB assesses implications of war in Iran

    80% confidence

  • Real-time risk premium for crude oil at $18/barrel, corresponding to impact of six-week full halt to tanker traffic in Strait of Hormuz

    80% confidence

  • Four of six tanks at Saudi Arabia's Ras Tanura refinery were full, and Ju'aymah terminal is quickly running out of spare capacity

    80% confidence

  • Broadcom expects its AI chip sales to top $100 billion next year

    80% confidence

  • Most of American Eagle Outfitters' profit will be generated in the second half of the year

    80% confidence

  • Prolonged conflict in Middle East would risk pushing inflation expectations higher

    80% confidence

  • Excluding Magnificent Seven megacap tech stocks, Q4 earnings expected to increase by 4.6%

    80% confidence

  • Fastenal February daily sales rate estimate of 7.2%

    80% confidence

  • Astera Labs rated buy with $250 price target

    80% confidence

  • S&P earnings growth expected to climb by 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence

  • Ships sailing through Strait of Hormuz could be at risk from missiles or rogue drones

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stocks Pressured by Rising Oil Prices and Bond Yields — Source | Via News | ViaNews EU